A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

234

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Advanced CancerAdvanced Solid Tumor

Interventions

DRUG

ALK202

Administered intravenously, once every 3 weeks

Trial Locations (4)

RECRUITING

Scientia Clinical Research Ltd, Randwick

RECRUITING

Macquarie University, Sydney

RECRUITING

Next Oncology, Fairfax

RECRUITING

D&H Cancer Research Center Llc, Margate

All Listed Sponsors

lead

Shanghai Allink Biotherapeutics Co., Ltd.

INDUSTRY